Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Japanese participant must be 18 years or older at the time of signing the informed consent.~* Participants who have a clinical diagnosis of aTTP (initial or recurrent), which includes thrombocytopenia (defined as platelet count \<100,000/µL), microangiopathic hemolytic anemia as evidenced by red blood cell fragmentation (eg, presence of schistocytes), and increased levels of LDH~* Participants who require initiation of daily PE treatment and have received a maximum of 1 PE treatment prior to enrollment in the study~* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies~* Capable of giving signed informed consent~Exclusion criteria:~* Platelet count ≥100,000/µL,~* Serum creatinine level \> 2.3mg/dL in case platelet count is \> 30,000µL~* Known other causes of thrombocytopenia~* Congenital TTP~* Clinically significant active bleeding or high risk of bleeding~* Malignant arterial hypertension~* Known chronic treatment with anticoagulant treatment that cannot be stopped~* Participants who were previously enrolled in a clinical study with caplacizumab and received caplacizumab or for whom the assigned treatment arm is unknown~* Participants currently or less than 28 days prior to enrollment in this study, enrolled in a clinical study with another investigational drug or device~* Clinical condition other than that associated with TTP, with life expectancy \< 6 months, such as end-stage malignancy~* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study~* Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caplacizumab (Type: EXPERIMENTAL): Eligible study participants will receive caplacizumab in addition to standard of care such as daily plasma exchange (PE) and corticosteroid treatment (mandatory), immunosuppressive treatment (if needed)

Based on this trial design, predict the completion outcome and termination type (if applicable).